Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High‐Dose Statin Therapy-Reference-Cited by-同舟云学术

Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High‐Dose Statin Therapy

Published:2013-03-12 Issue:2 Volume:2 Page:
ISSN:2047-9980
Container-title:Journal of the American Heart Association
language:en
Short-container-title:JAHA

Author:

Raal Frederick¹,Panz Vanessa¹,Immelman Andrew¹,Pilcher Gillian¹

Affiliation:

1. Carbohydrate and Lipid Metabolism Research Unit, Department of Medicine, University of the Witwatersrand, Johannesburg, South Africa

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference32 articles.

1. Update and Analysis of the University College London Low Density Lipoprotein Receptor Familial Hypercholesterolemia Database

2. Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment

3. Genetic defects causing familial hypercholesterolaemia: Identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic

4. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of PCSK9 on thrombosis and haemostasis in a variety of metabolic states: Lipids and beyond (Review);International Journal of Molecular Medicine;2024-05-10

2. Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?;Current Atherosclerosis Reports;2024-01-02

3. High-Fat Diet Enhances Platelet Activation and Is Associated with Proprotein Convertase Subtilisin Kexin 9: An Animal Study;Nutrients;2023-10-21

4. PCSK9 activation promotes early atherosclerosis in a vascular microphysiological system;APL Bioengineering;2023-10-16

5. Targeting PCSK9 to tackle cardiovascular disease;Pharmacology & Therapeutics;2023-09